India, March 13 -- Amgen Inc. (AMGN) Thursday announced positive data from the Phase 3 MINT study of Uplizna in adults with generalized myasthenia gravis (gMG).
Myasthenia gravis is a chronic autoimmune disorder that causes weakness in the voluntary muscles.
The Phase 3 MINT study is designed to evaluate Uplizna in muscle-specific kinase autoantibody-positive (MuSK+) and acetylcholine receptor autoantibody-positive (AChR+) gMG patients, with the MuSK+ group followed for 26 weeks and the AChR+ group followed for 52 weeks. Results from the study demonstrated durable and sustained efficacy of Uplizna in AChR+ gMG patients with two doses a year, following an initial loading dose.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-...